Inhalation Anesthesia Market Size To Reach USD 2.82 Billion By 2032, Fueled By Rising Surgical Volumes And Technological Advancements S&S Insider

(MENAFN- GlobeNewsWire - Nasdaq) Sevoflurane dominates market share, while desflurane adoption accelerates with growing outpatient surgery demand and low-flow anesthesia techniques.

Austin, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Inhalation Anesthesia Market Size & Growth Analysis

According to S&S Insider, the global Inhalation Anesthesia Market was valued at USD 1.69 billion in 2024 and is projected to reach USD 2.82 billion by 2032, growing at a CAGR of 6.66% over 2025–2032. The U.S. inhalation anesthesia market is expected to expand from USD 0.66 billion to USD 1.07 billion over the same period, at a CAGR of 6.39%. Growth is being fueled by the rising number of surgical procedures worldwide, innovations in anesthesia delivery systems, and the preference for short-acting agents like sevoflurane and desflurane. Increasing geriatric and pediatric populations, coupled with growing surgical infrastructure in emerging markets, are adding momentum to market expansion.

Get Sample Report of Inhalation Anesthesia Market @

The market is witnessing steady growth as hospitals and ambulatory surgical centers (ASCs) adopt advanced, digitally controlled vaporizers and closed-circuit anesthesia systems. These innovations reduce anesthetic waste, improve accuracy, and integrate seamlessly with electronic health records, boosting both patient safety and operational efficiency.

Demand is further driven by the growing preference for inhalation induction in children and elderly patients, who often face challenges with IV access. Sevoflurane's pleasant smell, minimal airway irritation, and fast onset make it an ideal choice for mask induction in pediatric and ambulatory settings.

Major Players Analysis Listed in the Inhalation Anesthesia Market Report are

• Baxter International Inc.
• AbbVie Inc.
• Piramal Critical Care
• Hikma Pharmaceuticals PLC\
• Fresenius Kabi AG
• Halocarbon Life Sciences, LLC
• Lunan Pharmaceutical Group Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Beijing Tongrentang Co., Ltd.
• Troikaa Pharmaceuticals Ltd.
• Boehringer Ingelheim International GmbH
• Abbott Laboratories
• Novartis AG
• AstraZeneca plc
• Maruishi Pharmaceutical Co., Ltd.
• Mylan N.V. (Viatris Inc.)
• Shanghai Hengrui Pharmaceutical Co., Ltd.
• Drägerwerk AG & Co. KGaA
• Mindray Medical International Limited
• GE HealthCare Technologies Inc.

Inhalation Anesthesia Market Report Scope

Report Attributes	Details
Market Size in 2024	USD 1.69 Billion
Market Size by 2032	USD 2.82 Billion
CAGR	CAGR of 6.66% From 2025 to 2032
Base Year	2024
Forecast Period	2025-2032
Historical Data	2021-2023
Regional Analysis	North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)

Segmentation Analysis:

By Drug

Due in large part to its benefits, such as quick induction and recovery, low pungency, and a high safety margin, the sevoflurane segment held a 40.6% market share in 2024 for inhalation anesthetic, making it the go-to option for both adult and pediatric procedures. Due to its extremely quick onset and emergence, desflurane is anticipated to have the highest CAGR during the projection period in both ambulatory and outpatient surgical settings.

By Application

The maintenance segment dominated the inhalation anesthesia market in 2024 with a 68.2% market share due to the increasing use of different drugs in inhalation anesthesia to maintain anesthesia during surgeries. Due to the increased demand for inhalation induction, especially among pediatric and geriatric patients for whom venous access can be challenging, the induction sector is expected to grow at the greatest CAGR throughout the forecast period.

By Patient Type

Due to the high frequency of numerous surgical procedures, including orthopedic, cardiovascular, and general operations, conducted on the adult population, the adult segment represented the highest share of the inhalation anesthesia market in 2024. Throughout the projection period, the pediatric segment is anticipated to expand significantly due to rising global awareness and easier access to pediatric surgical care.

By End-Use

In 2024, the hospital segment represented the largest portion of the inhalation anesthesia market, comprising 66.34% of the total share. The prevalence of complex and high-risk surgeries in hospitals necessitates continuous monitoring and advanced anesthesia management, which significantly contributes to the prominence of this end-user segment. The Ambulatory Surgical Centers (ASCs) segment is expected to demonstrate the highest growth during the forecast period due to the increasing global inclination towards outpatient and day surgeries.

Need Any Customization Research on Inhalation Anesthesia Market, Enquire Now:

Inhalation Anesthesia Market Key Segments

By Drug

• Sevoflurane
• Desflurane
• Isoflurane

By Application

• Induction
• Maintenance

By Patient Type

• Pediatric
• Adult

By End Use

• Hospitals
• Ambulatory Surgical Centers

Regional Analysis

North America dominated the market in 2024, holding a 51.1% share, driven by high surgical volumes, robust reimbursement systems, and early adoption of digital anesthesia workstations and low-flow techniques. The U.S. leads in R&D investments, which supports rapid adoption of innovative inhalation anesthetics and delivery technologies.

Asia Pacific is projected to grow at the highest CAGR (6.65%) through 2032, supported by expanding surgical infrastructure, government initiatives to improve healthcare access, and rising medical tourism in countries like India, Thailand, and Malaysia. China's expanding hospital network and increasing awareness of modern anesthesia techniques are also contributing significantly to growth.

Recent News:

• March 2025 – Hikma Pharmaceuticals PLC , an international pharmaceutical company, revealed the U.S. launch of Cisatracurium Besylate Injection, USP. The drug is available in 200mg/20mL and 20mg/10mL formulations, adding to Hikma's portfolio of anesthesia products.
• April 2024 – Baxter International Inc., a leading manufacturer of anesthesia, injectables, and drug compounding, announced the addition of its U.S. pharmaceuticals portfolio with the launch of five new injectable products, affirming its commitment to hospital-based care solutions.

Buy the Inhalation Anesthesia Market Report Now:

Exclusive Sections of the Report (The USPs):

• INCIDENCE & PREVALENCE ANALYSIS – helps you understand the global volume of surgical procedures requiring inhalation anesthesia, disease prevalence across orthopedic, cardiovascular, and cancer cases, and the impact of aging and pediatric populations on anesthesia demand.
• ANESTHETIC AGENT USAGE TRENDS – helps you track the dominance of sevoflurane, continued reliance on isoflurane in cost-sensitive regions, the decline of desflurane due to environmental concerns, and the adoption of low-flow anesthesia practices.
• TECHNOLOGICAL ADOPTION & INFRASTRUCTURE DEVELOPMENT – helps you evaluate the rise of automated vaporizers, smart anesthesia systems, expansion of ambulatory surgical centers, and modernization of operating room infrastructure in emerging economies.
• REGULATORY & ENVIRONMENTAL INFLUENCE – helps you analyze the role of global regulations, sustainability pressures due to anesthetic GWP, institutional eco-friendly policies, and the advancement of next-generation green anesthetics.
• COMPETITIVE LANDSCAPE – helps you benchmark key players' strengths, product portfolios, geographic presence, R&D initiatives, and strategic responses to evolving regulatory and environmental challenges.

Access Complete Report Details of Inhalation Anesthesia Market Analysis & Outlook@

[For more information or need any customization research mail us at ...]

About Us:

S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: ...

MENAFN24092025004107003653ID1110104424